Terapia dialéctico conductual para el trastorno de personalidad límite

Dialectical behavior therapy (DBT) is a third generation psychological therapy developed by Marsha Linehan (1993a, 1993b) to specifically manage the characteristic symptoms of borderline personality disorder: affective instability, identity disorder, impulsivity and difficulties in social relationships. The DBT comes from a biosocial model of BPD and combine cognitive behavioral techniques with Zen and Buddhist concepts based on an acceptance of reality as presented. The treatment consists of skills training, individual psychotherapy and crisis intervention and it is carried out by a coordinated team of professionals engaged in different functions. The DBT has efficacy studies and it is being successfully applied to other populations of patients with high impulsivity.ResumenLa terapia dialéctico conductual (TDC) es una terapia psicológica de tercera generación desarrollada por Marsha Linehan (1993a, 1993b) para tratar específicamente los síntomas característicos del trastorno límite de la personalidad: inestabilidad afectiva, trastorno de identidad, impulsividad y dificultades en las relaciones sociales. La TDC parte de un modelo biosocial del trastorno límite y combina técnicas cognitivo conductuales con aproximaciones zen y budistas basadas en la aceptación de la realidad tal como se presenta. El tratamiento consiste en un entrenamiento en habilidades, psicoterapia individual y atención en crisis y es llevado a cabo por un equipo coordinado de profesionales que ejercen distintas funciones. La TDC cuenta con estudios de eficacia y se está aplicando con éxito a otras poblaciones de pacientes con elevada impulsividad.AbstractDialectical behavior therapy (DBT) is a third generation psychological therapy developed by Marsha Linehan (1993a, 1993b) to specifically manage the characteristic symptoms of borderline personality disorder: affective instability, identity disorder, impulsivity and difficulties in social relationships. The DBT comes from a biosocial model of BPD and combine cognitive behavioral techniques with Zen and Buddhist concepts based on an acceptance of reality as presented. The treatment consists of skills training, individual psychotherapy and crisis intervention and it is carried out by a coordinated team of professionals engaged in different functions. The DBT has efficacy studies and it is being successfully applied to other populations of patients with high impulsivity

Introducción al tratamiento basado en la mentalización para el trastorno límite de la personalidad

Mentalization based treatment (MBT) for Borderline Personality Disorder (BPD) has been developed mainly by Anthony Bateman and Peter Fonagy. Mentalization is the process by which we understand others and ourselves in terms of subjective states (wishes, thoughts, feelings) and the close link between these and our behaviors. Such ability is not innate: it must develop in a secure attachment context. According to this model, the BPD symptoms result from the re-emergence of pre-mentalizing modes of psychic functioning, after a partial and specific suppression of mentalizing in a context of hyperactivation of the attachment system. In Hallwick Unit (Hospital St. Ann, London), conducted by Bateman, treatment is structured in three phases, keeping focus on enhancing mentalization. It has been proved effective in reducing borderline symptoms in randomized controlled trials, which support its usage.ResumenLa terapia basada en la mentalización (TBM) para el Trastorno Límite de Personalidad (TLP) ha sido desarrollada principalmente por Anthony Bateman y Peter Fonagy. La mentalización es el proceso mediante el cual entendemos a los otros y a nosotros mismos en términos de estados subjetivos (deseos, pensamientos, sentimientos), y la estrecha relación de nuestras conductas con los mismos. Esta capacidad no es innata: debe desarrollarse en un contexto de apego seguro. Según este modelo, los síntomas del TLP resultan del re-surgimiento de modos pre-mentalizadores de funcionamiento psíquico tras una supresión parcial y específica de la mentalización, ocurrida en un contexto de hiperactivación del sistema de apego. En la Unidad de Hallwick (Hospital St. Ann, Londres), dirigida por Bateman, el tratamiento se estructura en tres fases, centrándose en favorecer la mentalización. Su efectividad en la reducción de los síntomas borderline ha quedado demostrada en ensayos controlados aleatorizados que justifican su utilidad.AbstractMentalization based treatment (MBT) for Borderline Personality Disorder (BPD) has been developed mainly by Anthony Bateman and Peter Fonagy. Mentalization is the process by which we understand others and ourselves in terms of subjective states (wishes, thoughts, feelings) and the close link between these and our behaviors. Such ability is not innate: it must develop in a secure attachment context. According to this model, the BPD symptoms result from the re-emergence of pre-mentalizing modes of psychic functioning, after a partial and specific suppression of mentalizing in a context of hyperactivation of the attachment system. In Hallwick Unit (Hospital St. Ann, London), conducted by Bateman, treatment is structured in three phases, keeping focus on enhancing mentalization. It has been proved effective in reducing borderline symptoms in randomized controlled trials, which support its usage

Indicadores asistenciales y estándares de calidad asistencial para la psicología clínica en los centros de salud mental del Sistema Madrileño de Salud evaluados por sus profesionales

La disponibilidad en España de indicadores y estándares de calidad asistencial para Psicología Clínica en el Sistema Nacional de Salud es limitada. En este trabajo analizamos indicadores y estándares asistenciales ambulatorios informados por 107 Facultativos de Psicología Clínica en Centros de Salud Mental del Servicio Madrileño de Salud, a través de una encuesta online completada en 2021. El tiempo medio para la primera consulta normal en adultos fue de 4 meses y 5 en infanto-juvenil. El tiempo medio entre sesiones en ambos fueron 7 semanas. El número medio de pacientes nuevos semanales es de 8 y 6 en adultos e infanto-juvenil y de pacientes diarios fue de 9 y 8 respectivamente. La carga media total es 328 pacientes en adultos y 280 en infanto-juvenil. Sin embargo, los encuestados creen que la carga de pacientes activos debería ser 74, sin superar los 150 y un máximo de 6 al día. La mayoría de los psicólogos/as clínicos/as propone aumentar el número de plazas PIR y apoya la creación de Servicios de Psicología Clínica. La carga asistencial supera las recomendaciones de otros expertos. Se concluye que es imprescindible aumentar la ratio de psicólogos/as clínicos/as para alcanzar los estándares recomendados.Indicators and standards of care quality for Clinical Psychology in the National Health System are limited in Spain. In this work, outpatients’ indicators and standards reported by 107 Clinical Psychologists in Mental Health Centers of the Madrid Health Service were analyzed, through an online survey completed in 2021. The average waiting list for the first normal appointment in adults was 4 months and 5 in children. The mean time between sessions in both was 7 weeks. The average number of new weekly patients is 8 and 6 in adults and children and adolescents, and of daily patients was 9 and 8, respectively. The total mean load was 328 patients in adults and 280 in children. However, the participants believe that the active patient load should be 74, without exceeding 150, and a maximum of 6 per day. Most clinical psychologists propose to increase the number of PIR positions and support the creation of Clinical Psychology Services. The care burden exceeds the recommendations of other experts. It is concluded that it is essential to increase the ratio of clinical psychologists to reach the recommended standards

MAPPING COMMUNITY INTEREST HABITATS IN THE COLUMBRETES ARCHIPELAGO, AN EXTRAORDINARY HOT SPOT OF BIODIVERSITY

The Columbretes Archipelago and their submerged surroundings are part of an unusual, Pleistocene volcanic field located in the Western Mediterranean designated as a Site of Community Importance (SCI) of the Natura 2000 Network. In the present study, 4 benthic habitats of community interest (1110, 1170, 1180 and 8330) have been identified by analyzing several sources of information. Generalized additive models (GAMs) have been used to model the potential distribution of reefs (1170) and maërl beds (1110). Our results highlight the diversity and extent of these habitats and allow comparisons to other marine SCIs of Spain. This can be attributed to the variability of the environment of this site. The Columbretes Islands combine a relatively shallow environment with volcanic structures, hydrothermalism with active degassing, current-driven sedimentary lobes and the influence of inland flows. Understanding high biodiversity spots is crucial as they offer natural laboratories to describe how ecosystems respond to the effects of global change. The knowledge obtained will be of paramount importance for the conservation of species and habitats. Furthermore, it will establish a baseline for future monitoring and assist in the development of effective management plans

Safety and effectiveness of CIMAvax-EGF administered in community polyclinics

In spite of the advances in immunotherapy and targeted therapies, lung cancer continues to be the leading cause of cancer-related death. The epidermal growth factor receptor is an established target for non-small cell lung cancer (NSCLC), and its overactivation by the ligands can induce accelerated proliferation, angiogenesis, and metastasis as well as proinflammatory or immunosuppressive signals. CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy that is approved for the treatment of NSCLC patients in Cuba. The study was designed as a phase IV trial to characterize the safety and effectiveness of CIMAvax-EGF in advanced NSCLC patients treated in 119 community polyclinics and 24 hospitals. CIMAvax-EGF treatment consisted of four bi-weekly doses followed by monthly boosters. Overall, 741 NSCLC patients ineligible for further cancer-specific treatment were enrolled. CIMAvax-EGF was safe, and the most common adverse events consisted of mild-to-moderate injection site reactions, fever, chills, tremors, and headache. For patients completing the loading doses, the median survival was 9.9 months. For individuals achieving at least stable disease to the frontline and completing vaccination induction, the median survival was 12 months. Most of the functional activities and symptoms evaluated through the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire improved over time. In conclusion, this real-world trial demonstrated that CIMAvax-EGF was safe and effective in patients who were vaccinated in the maintenance scenario. A larger effect was seen in subjects with poor prognosis like those with squamous tumors and high EGF levels. Remarkably, this community-based intervention was very important because it demonstrated the feasibility of treating advanced lung cancer patients with active immunotherapy in primary care institutions. In addition to CIMAvax-EGF, patients received supportive care at the community clinic. Vaccine administration by the family doctors at the polyclinics reduced the patients’ burden on the medical oncology services that continued providing chemotherapy and other complex therapies. We conclude that community polyclinics constitute the optimal scenario for administering those cancer vaccines that are safe and require prolonged maintenance in patients with advanced cancer, despite the continuous deterioration of their general condition.Clinical trial registrationhttps://rpcec.sld.cu/trials/RPCEC00000205-En, identifier RPCEC00000205

Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus

Despite the high incidence of posttransplant diabetes mellitus (PTDM) among high-risk recipients, no studies have investigated its prevention by immunosuppression optimization. We conducted an open-label, multicenter, randomized trial testing whether a tacrolimus-based immunosuppression and rapid steroid withdrawal (SW) within 1 week (Tac-SW) or cyclosporine A (CsA) with steroid minimization (SM) (CsA-SM), decreased the incidence of PTDM compared with tacrolimus with SM (Tac-SM). All arms received basiliximab and mycophenolate mofetil. High risk was defined by age >60 or >45 years plus metabolic criteria based on body mass index, triglycerides, and high-density lipoprotein-cholesterol levels. The primary endpoint was the incidence of PTDM after 12 months. The study comprised 128 de novo renal transplant recipients without pretransplant diabetes (Tac-SW: 44, Tac-SM: 42, CsA-SM: 42). The 1-year incidence of PTDM in each arm was 37.8% for Tac-SW, 25.7% for Tac-SM, and 9.7% for CsA-SM (relative risk [RR] Tac-SW vs. CsA-SM 3.9 [1.2-12.4; P = 0.01]; RR Tac-SM vs. CsA-SM 2.7 [0.8-8.9; P = 0.1]). Antidiabetic therapy was required less commonly in the CsA-SM arm (P = 0.06); however, acute rejection rate was higher in CsA-SM arm (Tac-SW 11.4%, Tac-SM 4.8%, and CsA-SM 21.4% of patients; cumulative incidence P = 0.04). Graft and patient survival, and graft function were similar among arms. In high-risk patients, tacrolimus-based immunosuppression with SM provides the best balance between PTDM and acute rejection incidence

Reseñas iberoamericanas

Iberoamerican reviewsReseñas iberoamericana

Reseñas iberoamericanas

Reseñas iberoamericana

Role of age and comorbidities in mortality of patients with infective endocarditis

[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. [Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. [Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. [Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio